European journal of respiratory diseases. Supplement最新文献

European journal of respiratory diseases. Supplement Pub Date : 2008-01-01 DOI: 10.1007/978-3-540-77385-6_10

Jiade J. Lu

引用次数: 4

European journal of respiratory diseases. Supplement Pub Date : 1987-03-01 DOI: 10.1378/CHEST.91.3_SUPPLEMENT.11S

L. D. de Leij, H. Berendsen, H. The

{"title":"Small cell lung cancer.","authors":"L. D. de Leij, H. Berendsen, H. The","doi":"10.1378/CHEST.91.3_SUPPLEMENT.11S","DOIUrl":"https://doi.org/10.1378/CHEST.91.3_SUPPLEMENT.11S","url":null,"abstract":"It can be stated that, depending on the type of lung cancer, the best opportunity for curative treatment is in the early stage of disease, when cancer is limited to the lung and surgical intervention can be indicated. Especially in the case of SCLC, the number of patients presenting with such a limited disease is very low. In SCLC, chemo- and/or radiotherapy can induce initial good responses, which, although not curative in most cases, can elongate life for an average of 10 months. Although changes and refinements in treatment are continuously introduced, further progresses in the outcome have not achieved for the last decennium. Therefore, more fundamental research is needed to indicate new treatment avenues. A number of findings appear promising in this field. Firstly, the development of tissue culture techniques has enabled a better study of the biological properties of both SCLC and non-SCLC. Secondly, the development of monoclonal antibodies has refined the possibilities to type lung cancer. Particularly if monoclonal antibodies could be identified which occurrence turns out to be relevant to prognosis, immunohistopathology could become an important additional tool for the assessment of a pathological diagnosis in lung cancer. In addition, monoclonal antibodies which are specific for lung cancer could be used for an immunotherapeutical approach in the near future. Such a treatment might complement currently available treatment modalities.","PeriodicalId":12048,"journal":{"name":"European journal of respiratory diseases. Supplement","volume":"34 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"1987-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81548553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone. 蒽环类相关化合物在阿霉素敏感的人小细胞肺癌细胞系及其阿霉素耐药后代中的活性阿霉素、柔红霉素、4-脱氧柔红霉素、4-去甲氧基柔红霉素、去柔红霉素、4'-外柔红霉素和米托蒽醌的活性。